{"id":177037,"date":"2018-01-15T01:56:02","date_gmt":"2018-01-15T01:56:02","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=177037"},"modified":"2018-01-15T01:56:02","modified_gmt":"2018-01-15T01:56:02","slug":"rhinoconjunctivitis-pharmaceutical-and-healthcare-pipeline-review-h2","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rhinoconjunctivitis-pharmaceutical-and-healthcare-pipeline-review-h2_177037.html","title":{"rendered":"Rhino-Conjunctivitis Pharmaceutical and Healthcare Pipeline Review H2"},"content":{"rendered":"
Pune, India, 15th January 2018: WiseGuyReports announced addition of new report, titled \u201cRhino-Conjunctivitis – Pipeline Review, H2 2017\u201d.\t\t<\/div>\n

Summary<\/strong><\/p>\n

Rhinitis<\/a><\/strong> is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.<\/p>\n

 <\/p>\n

Report Highlights<\/strong><\/p>\n

Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.<\/p>\n

 <\/p>\n

GET SAMPLE REPORT @ https:\/\/www.wiseguyreports.com\/sample-request\/2740084-rhino-conjunctivitis-pipeline-review-h2-2017<\/a>        <\/em><\/strong><\/p>\n

 <\/p>\n

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies \/Universities \/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 9, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.<\/p>\n

 <\/p>\n

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.<\/p>\n

 <\/p>\n

Scope<\/strong><\/p>\n

– The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).<\/p>\n

– The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities\/research institutes based on information derived from company and industry-specific sources.<\/p>\n

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.<\/p>\n

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.<\/p>\n

– The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.<\/p>\n

– The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.<\/p>\n

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.<\/p>\n

– The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)<\/p>\n

 <\/p>\n

Reasons to buy<\/strong><\/p>\n

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.<\/p>\n

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.<\/p>\n

– Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).<\/p>\n

– Classify potential new clients or partners in the target demographic.<\/p>\n

– Develop tactical initiatives by understanding the focus areas of leading companies.<\/p>\n

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.<\/p>\n

– Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.<\/p>\n

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.<\/p>\n

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.<\/p>\n

 <\/p>\n

Table of Content: Key Points<\/strong><\/p>\n

List of Tables<\/p>\n

List of Figures<\/p>\n

Introduction<\/p>\n

Rhino-Conjunctivitis – Overview<\/p>\n

Rhino-Conjunctivitis – Therapeutics Development<\/p>\n

Pipeline Overview<\/p>\n

Pipeline by Companies<\/p>\n

Pipeline by Universities\/Institutes<\/p>\n

Products under Development by Companies<\/p>\n

Products under Development by Universities\/Institutes<\/p>\n

Rhino-Conjunctivitis – Therapeutics Assessment<\/p>\n

Assessment by Target<\/p>\n

Assessment by Mechanism of Action<\/p>\n

Assessment by Route of Administration<\/p>\n

Assessment by Molecule Type<\/p>\n

Rhino-Conjunctivitis – Companies Involved in Therapeutics Development<\/p>\n

ALK-Abello AS<\/p>\n

Allergopharma GmbH & Co KG<\/p>\n

Allergy Therapeutics Plc<\/p>\n

ASIT Biotech SA<\/p>\n

Astellas Pharma Inc<\/p>\n

Bial – Portela & Ca SA<\/p>\n

Faes Farma SA<\/p>\n

Griffin Discoveries BV<\/p>\n

HAL Allergy BV<\/p>\n

Laboratorios LETI SL<\/p>\n

Oxagen Ltd<\/p>\n

Rhino-Conjunctivitis – Drug Profiles<\/p>\n

Acaroid – Drug Profile<\/p>\n

Product Description<\/p>\n

…Continued                             <\/strong><\/p>\n

 <\/strong><\/p>\n

ACCESS REPORT @ https:\/\/www.wiseguyreports.com\/reports\/2740084-rhino-conjunctivitis-pipeline-review-h2-2017<\/a>  <\/em><\/strong><\/p>\n

                                         <\/em><\/strong>                        <\/strong><\/p>\n

Get in touch:                                                          <\/strong><\/p>\n

LinkedIn: <\/strong>www.linkedin.com\/company\/4828928<\/strong><\/a><\/p>\n

Twitter: <\/strong>https:\/\/twitter.com\/WiseGuyReports<\/strong><\/a>                                                                   <\/strong><\/p>\n

Facebook: <\/strong>https:\/\/www.facebook.com\/Wiseguyreports-1009007869213183\/?fref=ts<\/strong>    <\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com
Contact Person:<\/strong> Norah Trent
Email:<\/strong> sales@wiseguyreports.com
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Pune, India, 15th January 2018: WiseGuyReports announced addition of new report, titled \u201cRhino-Conjunctivitis – Pipeline Review, H2 2017\u201d. Summary Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-177037","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/177037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=177037"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/177037\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=177037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=177037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=177037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}